Orthofix International | OFIX - Selling And Administration Expenses


Orthofix International reported $130.35M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Accuray USD 124.78M 2.54M Dec/2025
AngioDynamics USD 36.57M 3.79M Sep/2025
Artivion USD 55.75M 4.54M Dec/2025
AtriCure USD 82.88M 319K Sep/2026
Dexcom USD 358.7M 9M Jun/2026
EDAP TMS EUR 12.92M 4.1M Mar/2026
Globus Medical USD 288.47M 1.65M Sep/2026
Inogen USD 43.77M 510K Jun/2024
Insulet USD 350.7M 5.9M Sep/2026
Integra LifeSciences USD 161.02M 5.2M Sep/2026
J&J USD 6.25B 168M Sep/2026
Medtronic 3.2B 141M Jun/2026
Mesa Laboratories USD 27.31M 380K Sep/2024
Orthofix International USD 130.35M 11.31M Dec/2025
Plus Therapeutics USD 4.26M 779K Mar/2026
Smith & Nephew USD 1.45B 29M Jun/2026
STAAR Surgical USD 43.22M 1.92M Sep/2026
Stryker USD 2.12B 32M Jun/2026
Tandem Diabetes Care USD 111.64M 3.45M Jun/2026
Teleflex USD 220.72M 7.21M Sep/2026
Veracyte USD 57.95M 2.25M Sep/2026
Zimmer Biomet Holdings USD 855M 56.6M Sep/2026